134 related articles for article (PubMed ID: 1720302)
1. Characterization of purified gp 51 from bovine leukemia virus integrated into iscom. Physicochemical properties and serum antibody response to the integrated gp51.
Merza M; Söber J; Sundquist B; Toots I; Morein B
Arch Virol; 1991; 120(3-4):219-31. PubMed ID: 1720302
[TBL] [Abstract][Full Text] [Related]
2. Bovine leukaemia virus ISCOMs: biochemical characterization.
Merza MS; Linné T; Höglund S; Portetelle D; Burny A; Morein B
Vaccine; 1989 Feb; 7(1):22-8. PubMed ID: 2541575
[TBL] [Abstract][Full Text] [Related]
3. Elicitation of bovine antibody to BLV-gp51 by BLV-vaccination.
Maruyama K; Fukushima T; Mochizuki S; Abe H; Onuma M; Hasegawa A; Misawa M
Leukemia; 1988 Dec; 2(12 Suppl):216S-222S. PubMed ID: 2848999
[TBL] [Abstract][Full Text] [Related]
4. Immunoaffinity purification of two major proteins of bovine leukemia virus (gp51 and p24) and their use for discrimination between vaccinated and infected animals.
Merza M; Sundquist B; Söber J; Morein B
J Virol Methods; 1991 Aug; 33(3):345-53. PubMed ID: 1723735
[TBL] [Abstract][Full Text] [Related]
5. Synthetic peptides approach to identification of epitopes on bovine leukemia virus envelope glycoprotein gp51.
Portetelle D; Dandoy C; Burny A; Zavada J; Siakkou H; Gras-Masse H; Drobecq H; Tartar A
Virology; 1989 Mar; 169(1):34-41. PubMed ID: 2466371
[TBL] [Abstract][Full Text] [Related]
6. Production of monoclonal antibody to bovine leukemia virus glycoprotein gp51 by in vitro immunization.
Sasaki O; Tanaka M; Okabe T; Imanishi J
Microbiol Immunol; 1990; 34(4):401-5. PubMed ID: 2163485
[TBL] [Abstract][Full Text] [Related]
7. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
Osterhaus A; Weijer K; Uytdehaag F; Jarrett O; Sundquist B; Morein B
J Immunol; 1985 Jul; 135(1):591-6. PubMed ID: 2987351
[TBL] [Abstract][Full Text] [Related]
8. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
[TBL] [Abstract][Full Text] [Related]
9. Development of a specific serological test and an efficient subunit vaccine to control bovine leukemia virus infection.
Portetelle D; Burny A; Desmettre P; Mammerickx M; Paoletti E; Zavada J
Dev Biol Stand; 1990; 72():81-90. PubMed ID: 1704325
[TBL] [Abstract][Full Text] [Related]
10. Delivery of pseudorabies virus envelope antigens enclosed in immunostimulating complexes (ISCOMs); elicitation of neutralizing antibody and lymphoproliferative responses in swine and protection in mice.
Tulman ER; Garmendia AE
Vaccine; 1994 Nov; 12(14):1349-54. PubMed ID: 7856303
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of common B cell epitope in bovine leukemia virus via high-throughput peptide screening system in infected cattle.
Bai L; Otsuki H; Sato H; Kohara J; Isogai E; Takeshima SN; Aida Y
Retrovirology; 2015 Dec; 12():106. PubMed ID: 26715158
[TBL] [Abstract][Full Text] [Related]
12. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene.
Weijer K; Pfauth A; van Herwijnen R; Jarrett O; Meloen RH; Tomee C; Osterhaus AD
Vaccine; 1993; 11(9):946-56. PubMed ID: 7692683
[TBL] [Abstract][Full Text] [Related]
13. Expression of the bovine leukemia virus envelope glycoprotein (gp51) by recombinant baculovirus and its use in an enzyme-linked immunosorbent assay.
De Giuseppe A; Feliziani F; Rutili D; De Mia GM
Clin Diagn Lab Immunol; 2004 Jan; 11(1):147-51. PubMed ID: 14715562
[TBL] [Abstract][Full Text] [Related]
14. Antigenic variants of bovine leukemia virus (BLV) are defined by amino acid substitutions in the NH2 part of the envelope glycoprotein gp51.
Portetelle D; Couez D; Bruck C; Kettmann R; Mammerickx M; Van der Maaten M; Brasseur R; Burny A
Virology; 1989 Mar; 169(1):27-33. PubMed ID: 2466370
[TBL] [Abstract][Full Text] [Related]
15. Identification of an immunodominant region on the isolated bovine leukaemia virus (BLV) major envelope protein gp51 by monoclonal antibodies presumably not exposed during natural BLV infection.
Platzer C; Siakkou H; Sober J; Kopp J; Scheve E; Rosenthal S
Acta Virol; 1990 May; 34(3):246-55. PubMed ID: 1980398
[TBL] [Abstract][Full Text] [Related]
16. Viral status and antibody response in cattle inoculated with recombinant bovine leukemia virus-vaccinia virus vaccines after challenge exposure with bovine leukemia virus-infected lymphocytes.
Cherney TM; Schultz RD
Am J Vet Res; 1996 Jun; 57(6):812-8. PubMed ID: 8725805
[TBL] [Abstract][Full Text] [Related]
17. Protective vaccination against bovine leukaemia virus infection by means of cell-derived vaccine.
Altaner C; Ban J; Altanerova V; Janik V
Vaccine; 1991 Dec; 9(12):889-95. PubMed ID: 1667347
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and immunological characterization of the bovine leukemia virus (BLV) envelope glycoprotein (gp51) produced in Saccharomyces cerevisiae.
Legrain M; Portetelle D; Dumont J; Burny A; Hilger F
Gene; 1989 Jul; 79(2):227-37. PubMed ID: 2551774
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of glycoprotein gII ISCOMs subunit vaccine for pseudorabies in pig.
Tsuda T; Sugimura T; Murakami Y
Vaccine; 1991 Sep; 9(9):648-52. PubMed ID: 1659053
[TBL] [Abstract][Full Text] [Related]
20. Formation and characterization of FeLV ISCOMs.
Akerblom L; Strömstedt K; Hoglund S; Osterhaus A; Morein B
Vaccine; 1989 Apr; 7(2):142-6. PubMed ID: 2750272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
